Feedback plc (LSE:FDBK), developer of the Bleepa clinical communication platform, is a company whose next twelve months could look nothing like its last twelve. On 14 July 2026 it told investors that a decision on a potential national contract with NHS England for Bleepa is anticipated around the end of the calendar year, subject to evaluation by NHS England and HM Treasury. For a Business generating under £1m of annual Revenue and valued at roughly £3m on AIM, the outcome is close to binary.

The key question is whether the NHS, after restructuring that management has called the toughest trading conditions it has known, finally converts years of pilots into a contract of scale — and whether Feedback's cash, guided to last only to mid-2027, holds out long enough.

Trading update: revenue flat, cash £2.7m, national decision slips to year-end

The 14 July 2026 trading update covered the year ended 31 May 2026. Revenue was approximately £0.8m, broadly flat against £0.89m a year earlier, and the EBITDA loss is expected to be lower than in FY25 as cost controls took effect. Year-end cash of £2.7m is said to fund the group to mid-2027.

The substance lay in the NHS pipeline. Feedback confirmed it is pursuing a national contract with NHS England for Bleepa, with a decision expected around the end of 2026. That is a further slip: on 20 April 2026 the company had disclosed that the central decision had been postponed by six to nine months for internal NHS reasons, while noting that discussions remained constructive and could align with new frontline digitisation funding for the 2026/27 NHS year.

Operationally, there was traction. Integrations were completed with the NHS e-Referral Service, which the company says produced a tenfold increase in GP referrals, and with Patients Know Best, enabling communication through the NHS App. In Sussex, 100% of breathlessness patients on the Bleepa pathway were diverted from outpatient appointments over the preceding three months.

Chief executive Dr Tom Oakley acknowledged "ongoing frustration around the lack of pace of NHS decision making" but said there were "grounds for optimism", calling the coming period "a pivotal moment for both the NHS and the Company".

Business overview: Bleepa and the shift from hospital to community care

Feedback plc, trading as Feedback Medical, sells software to the NHS. Its core product, Bleepa, lets clinicians in hospitals, GP surgeries and community settings share patient data, images and referrals asynchronously, so patients can be assessed and directed along a care pathway without necessarily attending an outpatient clinic. The company positions this against the NHS 10 Year Plan's shifts from analogue to digital and from hospital to community.

Bleepa generated 89% of revenue in the six months to 30 November 2025; legacy Cadran PACS licences and Imaging Engineering contributed the rest. Revenue is almost entirely UK-based; an Indian Subsidiary was paused after the FY25 year-end to conserve cash.

The anchor customer is Queen Victoria Hospital NHS Foundation Trust in Sussex, where NHS England extended Bleepa licences for nine months to December 2026 at an annualised £495,000, per the 20 April 2026 announcement. Northern Care Alliance NHS Foundation Trust agreed an annual extension, while a photocapture contract with Royal Berkshire NHS Foundation Trust lapsed in March 2026.

Financial performance: small revenue base, narrowing losses, shrinking cash

The most recent published accounts are the unaudited interims for the six months to 30 November 2025, released on 17 February 2026. Revenue fell 8% to £0.41m from £0.45m, and gross Margin slipped to 81% from 89% as the company invested in platform monitoring and new pathway roll-outs. The operating loss narrowed to £1.79m from £1.99m and the loss before tax to £1.72m from £1.95m, although the EBITDA loss widened to £1.61m from £1.43m after hiring developers and investing in cloud infrastructure. Loss per share was 3.98p against a restated 13.74p, the comparative having been corrected in a follow-up RNS the same day. Cash at 30 November 2025 was £3.82m and net Assets £4.46m.

For the year to 31 May 2025, reported on 17 September 2025, revenue fell 25% to £0.89m from £1.18m, the EBITDA loss widened to £3.06m from £2.73m, and the loss before tax doubled to £7.29m from £3.60m, inflated by a £3.19m Impairment of intangible assets attributed to NHS restructuring uncertainty. Year-end cash of £5.95m reflected a November 2024 placing and retail offer raising £6.1m gross. No Dividend is paid.

Cash is the number that matters: £5.95m at 31 May 2025, £3.82m by November 2025 and about £2.7m by 31 May 2026, implying a slower second-half burn. At 6.85p, with 43.81m shares in issue, Market Capitalisation at around £3.0m — close to balance-sheet cash. The shares hit a 52-week low of 6.05p on 14 August 2026, down from a February high of 14.75p.

What could drive the stock next?

The dominant catalyst is the NHS England national contract decision, guided for around the end of 2026 (LSE:FDBK). A positive outcome would transform a sub-£1m revenue base; a negative or delayed one would leave the company reliant on trust-level renewals. Feedback also expects Spending Review technology funding to reach the NHS frontline in 2026/27, and it has been selected to run two national Neighbourhood Health Service simulations.

Nearer term, audited results for the year to 31 May 2026 are due; last year's arrived on 17 September, and no date had been announced in the RNS feed reviewed at the time of writing. The December 2026 renewal at Queen Victoria Hospital and the strategic Partnership talks with consulting firms and cloud providers disclosed in February 2026 are further triggers. Chief financial officer Emma Oswick, who joined in November 2025, may also shape how any future funding is approached.

Risks investors should watch

Funding risk is foremost. A runway to mid-2027 means Feedback is likely to need fresh capital within about a year unless a large contract lands, and with a Market Value near £3m any Equity raise would be heavily dilutive.

Customer concentration is acute: a single Sussex trust accounts for the bulk of Bleepa revenue, and its licences run only to December 2026. The company depends on NHS procurement timetables it does not control, as two successive delays to the central decision have shown. Revenue has been flat to declining for two years, gross margin is compressing, and the FY25 impairment shows the board has already written down its own assessment of near-term prospects. Liquidity in the shares is thin.

Outlook

Feedback plc enters the autumn with a credible product, measurable clinical outcomes and a clearly defined catalyst, but also a cash position that leaves little margin for further NHS slippage. The full-year results will show whether the tighter cost base is holding and how management frames funding. After that, attention turns to the year-end NHS England decision, the Queen Victoria Hospital renewal and evidence that 2026/27 digitisation money is reaching the frontline. Each is knowable within months, which is why the shares, near their 52-week low, merit close monitoring.